Invention Grant
- Patent Title: 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability
-
Application No.: US17043912Application Date: 2019-03-21
-
Publication No.: US11713306B2Publication Date: 2023-08-01
- Inventor: Wei Zhong
- Applicant: Wayshine Biopharm Holding Limited
- Applicant Address: KY Grand Cayman
- Assignee: WAYSHINE BIOPHARM HOLDING LIMITED
- Current Assignee: WAYSHINE BIOPHARM HOLDING LIMITED
- Current Assignee Address: KY Grand Cayman
- Agency: Bayramoglu Law Offices LLC
- Priority: CN 1810313349.9 2018.04.09 CN 1810424472.8 2018.05.04
- International Application: PCT/CN2019/079047 2019.03.21
- International Announcement: WO2019/196622A 2019.10.17
- Date entered country: 2020-09-30
- Main IPC: C07D401/14
- IPC: C07D401/14 ; A61P35/00

Abstract:
5-substituted difluoropiperidine compounds having a capacity to cross the blood-brain barrier are provided. The compound has the structural formula represented by formula (I):
The 5-substituted difluoropiperidine compounds, derivatives and pharmaceutically acceptable salts thereof of the present invention have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a vascular endothelial growth factor receptor 2 or SRC kinase family (FYN) and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, primary brain cancer (glioma), glioblastoma, cancer with meningeal metastases, Alzheimer's disease and central nervous system diseases, and the like.
The 5-substituted difluoropiperidine compounds, derivatives and pharmaceutically acceptable salts thereof of the present invention have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a vascular endothelial growth factor receptor 2 or SRC kinase family (FYN) and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, primary brain cancer (glioma), glioblastoma, cancer with meningeal metastases, Alzheimer's disease and central nervous system diseases, and the like.
Public/Granted literature
- US20210017159A1 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY Public/Granted day:2021-01-21
Information query